Focused On-demand Library for Dedicator of cytokinesis protein 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:


Alternative UPACC:

Q96N67; Q00M63; Q2PPY7; Q45RE8; Q45RE9; Q5T1B9; Q5T1C0; Q6ZV32; Q8TB82; Q96NG6; Q96NI0; Q9C092


Dedicator of cytokinesis protein 7 (DOCK7) is a pivotal guanine nucleotide exchange factor (GEF) that activates Rac1 and Rac3 Rho small GTPases, facilitating GDP-GTP exchange. It plays a crucial role in axon formation, neuronal polarization, and cortical neurogenesis by regulating radial glial cell dynamics and septin-actin cytoskeleton interactions. DOCK7's involvement in pigmentation and its regulatory impact on microtubule growth highlight its multifaceted biological functions.

Therapeutic significance:

The association of DOCK7 with Developmental and epileptic encephalopathy 23, a condition marked by severe epilepsy, intellectual disability, and cortical blindness, underscores its therapeutic potential. Targeting DOCK7 could lead to innovative treatments for this debilitating disease, emphasizing the importance of understanding its biological mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.